China
Legislators Profit from Bill Restricting Chinese Biotech Firms
Congress, stock trading, China biotech ban, financial gain, legislative influence, conflict of interest.
Erasca Pivots Strategy, Secures $160M and Licenses Chinese Cancer Drugs Amidst Workforce Restructuring
Erasca, pipeline, workforce reduction, licensing, cancer drugs, China, $160M, strategic shift
Revival of Gene Editing Clinical Trials in China Post CRISPR Baby Scandal
CRISPR baby scandal, China, gene editing, clinical trials, restart, regulations, ethics, CRISPR-Cas9, genetic diseases, biotechnology.
Novo Nordisk Invests $556 Million in Manufacturing Amid Anticipation of Wegovy Approval in China
Novo Nordisk/ Wegovy/ China/ investment/ manufacturing expansion/ weight management
AstraZeneca Abandons Roxadustat’s US Future while Retaining Collaboration with FibroGen in China
FibroGen, roxadustat, China, Ultrasonography, AstraZeneca, Collaboration, chemotherapy-induced anemia, Retained
Lonza closes plant in China but CDMO’s sales signal an uptick in industry
Plants, China, Signal, Industry, Congestive heart failure